Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 1.00 |
| ▸ | PARP3 | Q9Y6F1 | 2/20 | 0.93 |
| ▸ | TNKS | O95271 | 1/20 | 0.76 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.76 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.76 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.76 |
| ▸ | PARP6 | Q2NL67 | 1/20 | 0.76 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.76 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.76 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.76 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.76 |
| ▸ | PARP8 | Q8N3A8 | 1/20 | 0.76 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.76 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.76 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.76 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.76 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.76 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30205023 | 1.00 | PARP1 (1.00) | PARP1PARP3TNKSADORA1CDK6 | |
| SCHEMBL29463415 | 1.00 | PARP1 (1.00) | PARP1PARP3TNKSADORA1CDK6 | |
| Hydrochloric Acid SCHEMBL29536089 | 0.99 | PARP1 (0.98) | PARP1PARP3TNKSADORA1CDK6 | |
| Hydrochloric Acid SCHEMBL23113141 | 0.99 | PARP1 (0.98) | PARP1PARP3TNKSADORA1CDK6 | |
| Hydrochloric Acid SCHEMBL22656793 | 0.99 | PARP1 (0.98) | PARP1PARP3TNKSADORA1CDK6 | |
| SCHEMBL864319 | 0.96 | PARP1 (1.00) | PARP1PARP3 | |
| SCHEMBL29434944 | 0.96 | PARP1 (1.00) | PARP1PARP3 | |
| SCHEMBL19569971 | 0.94 | PARP1 (0.90) | PARP1PARP3TNKSADORA1CDK6 | |
| SCHEMBL17781907 | 0.93 | PARP1 (0.86) | PARP1PARP3TNKSADORA1CDK6 | |
| SCHEMBL30293115 | 0.92 | PARP1 (0.89) | PARP1PARP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116803990-A | Preparation method of Olaparib | 天津法莫西医药科技有限公司 | 2023-09-26 | — | — | CN | claimed |
| CN-113603647-B | PARP inhibitor-alkylation bifunctional molecule and preparation method and application thereof | 潍坊医学院 | 2023-01-31 | — | — | CN | claimed |
| CN-106554316-B | A method of preparing 1- [5- [(3,4- dihydro -4- oxo -1- phthalazinyl) methyl] -2- fluoro benzoyl] piperazine | 上海医药集团股份有限公司 | 2019-03-08 | — | — | CN | claimed |
| CN-106554316-A | The method that one kind prepares 1- [5- [(3,4- dihydro -4- oxo -1- phthalazinyls) methyl] -2- fluoro benzoyls] piperazine | 上海医药集团股份有限公司 | 2017-04-05 | — | — | CN | claimed |
| EP-2374800-A2 | Methods for the preparation of 4-[3-(4-cyclopropanecarbonyl- piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | Kudos Pharmaceuticals Limited (GB) | 2011-10-12 | — | — | EP | claimed |
| US-7692006-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-04-06 | — | — | US | claimed |
| EP-2064189-A2 | POLYMORPHIC FORM OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | Kudos Pharmaceuticals Limited (GB) | 2009-06-03 | — | — | EP | claimed |
| US-20080146575-A1 | 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic with BRCA2 deficient phenotype; septic shock, ischemic injury, multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-06-19 | — | — | US | claimed |
| WO-2008047082-A2 | POLYMORPHIC FORM OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-24 | — | — | WO | claimed |
| EP-3504196-B1 | PROCESSES FOR PREPARING OLAPARIB | SCINOPHARM TAIWAN LTD (TW) | 2026-04-08 | — | — | EP | disclosed |
| US-12441757-B2 | Platform for screening NAD+ binding proteins in a cellular context | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2025-10-14 | — | — | US | disclosed |
| US-12398121-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20250127907-A1 | PARP INHIBITORS | Stablix, Inc. | 2025-04-24 | — | — | US | disclosed |
| EP-4446324-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| WO-2008047082-A2 | POLYMORPHIC FORM OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008047082-A2 | POLYMORPHIC FORM OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
| US-20060149059-A1 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| EP-1633724-A1 | PHTHALAZINONE DERIVATIVES | Kudos Pharmaceuticals Limited (GB) | 2006-03-15 | — | — | EP | disclosed |
| US-20050059663-A1 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2005-03-17 | — | — | US | disclosed |
| WO-2004080976-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12398121-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | PARP1 1873/4885PARP3 1005/4885TNKS 2187/4885 |
| US-20050059663-A1 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | PARP1 3029/4885PARP3 3491/4885TNKS 4048/4885 |
| US-20060149059-A1 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | PARP1 3176/4885PARP3 3644/4885TNKS 4111/4885 |
| US-20080146575-A1 | 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic with BRCA2 deficient phenotype; septic shock, ischemic injury, multiple sclerosis | PARP1, PARP11, PARP2 | PARP1 1/4885PARP3 4/4885TNKS 129/4885 |
| US-12441757-B2 | Platform for screening NAD+ binding proteins in a cellular context | SARM1, PARP16, PARP15 | PARP1 24/4885PARP3 28/4885TNKS 189/4885 |
| US-20250127907-A1 | PARP INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885PARP3 3/4885TNKS 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.